Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial
Elaine C. Siegfried(Saint Louis University), Ashish Bansal(Regeneron (United States)), Thomas Bieber(CK-CARE), Mark Boguniewicz(University of Colorado Denver), Lynda C. Schneider(Boston Children's Hospital), Lisa A. Beck(University of Rochester Medicine), Randy Prescilla(Sanofi (United States)), Paola Mina‐Osorio(Regeneron (United States)), Zhen Chen(The First People's Hospital of Shunde), Eric L. Simpson(Oregon Health & Science University), Faisal A. Khokhar(Regeneron (United States)), Amy S. Paller(Northwestern University)
Cited by 30
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k
Guidelines of care for the management of atopic dermatitis
|Journal of the American Academy of Dermatology|2013|1.3k